Open access
Open access
Powered by Google Translator Translator

Vaccines

Opinion: COVID-19 vaccine strategies must focus on severe disease and global equity.

17 Dec, 2021 | 09:45h | UTC

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

 

How COVID vaccines shaped 2021 in eight powerful charts.

17 Dec, 2021 | 09:44h | UTC

How COVID vaccines shaped 2021 in eight powerful charts – Nature

 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

15 Dec, 2021 | 08:43h | UTC

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

News release: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

 

Commentaries on Twitter

 

[Not published yet] Initial data from South Africa showed vaccine protection vs. Omicron infection may drop to 30% but does cut severe disease.

15 Dec, 2021 | 08:38h | UTC

Vaccine protection vs. omicron infection may drop to 30% but does cut severe disease – NPR

See also: South Africa Omicron study finds drop in vaccine protection, fewer hospitalized – CIDRAP

 

[Preprint] COVID vaccines cut the risk of transmitting Delta — but not for long

14 Dec, 2021 | 09:42h | UTC

COVID vaccines cut the risk of transmitting Delta — but not for long – Nature

Original Study [preprint]: The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission – medRxiv

 

An observational study showed Moderna is associated with increased effectiveness vs. Pfizer vaccine against symptomatic SARS-CoV-2 infection.

13 Dec, 2021 | 09:52h | UTC

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection – Med

Related:

Opinion | Is Moderna really better than Pfizer—or is it just a higher dose?

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

 

Commentary on Twitter

 

UK Report on SARS-CoV-2 variants of concern finds significantly lower vaccine effectiveness (VE) against Omicron infection, but a moderate to high VE of 70 to 75% is seen after a third (booster) dose.

13 Dec, 2021 | 09:53h | UTC

Report: SARS-CoV-2 variants of concern and variants under investigation in England – UK Health Security Agency

Commentaries:

Omicron: Three vaccine doses key for protection against variant – BBC

Two jabs offer little protection against Omicron infection, UK data shows – The Guardian

UK Says Omicron to Become Its Dominant Variant Within Days – Associated Press

 

Fauci says Omicron-specific version of Covid-19 vaccines may not be necessary.

13 Dec, 2021 | 09:51h | UTC

Fauci says Omicron-specific version of Covid-19 vaccines may not be necessary – STAT

 

Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine had 90% effectiveness at preventing death due to Covid-19 compared to a two-dose regimen.

9 Dec, 2021 | 10:35h | UTC

BNT162b2 Vaccine Booster and Mortality Due to Covid-19 – New England Journal of Medicine

Editorial: Booster Doses and Prioritizing Lives Saved

 

[Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant.

9 Dec, 2021 | 10:29h | UTC

Press release: Pfizer and Biontech provide update on Omicron variant

Commentaries:

Omicron likely to weaken COVID vaccine protection – Nature

Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP

Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre

Covid: Pfizer says booster shot promising against Omicron – BBC

Pfizer-BioNTech Covid-19 shot loses power against Omicron variant, but booster restores protection – STAT

 

Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine reduced the rates of confirmed Covid-19 and severe illness compared to a two-dose regimen.

9 Dec, 2021 | 10:32h | UTC

Protection against Covid-19 by BNT162b2 Booster across Age Groups – New England Journal of Medicine

Editorial: Booster Doses and Prioritizing Lives Saved

 

As 57 countries report Omicron cases, Pfizer says its boosters offer protection – but WHO cautions more research is needed.

9 Dec, 2021 | 10:28h | UTC

As 57 Countries Report Omicron Cases, Pfizer Says its Boosters Offer Protection – But WHO Cautions More Research is Needed – Health Policy Watch

See also: Covid: Vaccines should work against Omicron variant, WHO says – BBC

 

Multiple early studies find notable Omicron vaccine evasion.

9 Dec, 2021 | 10:26h | UTC

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

Related: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

 

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

8 Dec, 2021 | 10:22h | UTC

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Original Study: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

See also (thread – click for more)

 

Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule.

8 Dec, 2021 | 10:12h | UTC

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases

Invited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases

 

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

7 Dec, 2021 | 10:19h | UTC

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

News Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

 

Study shows increased immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.

7 Dec, 2021 | 10:21h | UTC

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

 

Commentary on Twitter (thread – click for more)

 

Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with significant variations in immune responses, UK trial shows.

5 Dec, 2021 | 23:57h | UTC

News Release: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows – The Lancet

Original Study: Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial – The Lancet

Commentaries:

Six different COVID-19 boosters induce variable immune response – CIDRAP

Covid booster shots significantly strengthen immunity, trial finds – The Guardian

Expert reaction to COV-BOOST study investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose following two doses of either Oxford-AstraZeneca or Pfizer – Science Media Centre

 

Commentary on Twitter

 

Omicron is supercharging the COVID vaccine booster debate – “The data are growing that booster jabs enhance protection — but their durability, impact and ability to quash the new variant are unknown”.

3 Dec, 2021 | 10:19h | UTC

Omicron is supercharging the COVID vaccine booster debate – Nature

 

Opinion | Omg, Omicron! Why it’s too soon to panic about COVID vaccines and the new variant.

3 Dec, 2021 | 10:16h | UTC

Omg, Omicron! Why it’s too soon to panic about COVID vaccines and the new variant – The Conversation

 

M-A: Observational data on the effectiveness of COVID-19 vaccines.

30 Nov, 2021 | 08:37h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 

Editorial: Vax the world.

26 Nov, 2021 | 08:40h | UTC

Vax the world – Science

 

Commentary from the author on Twitter

 

EMA recommends approval of Pfizer-BioNTech vaccine for children aged 5 to 11.

26 Nov, 2021 | 08:47h | UTC

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

Related:

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

 

Commentary on Twitter

 

Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

See also:

Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC

WHO calls special meeting to discuss new Covid variant found in South Africa with ‘a large number of mutations’ – CNBC

New COVID-19 Variant With Multiple Concerning Mutations Identified in Southern Africa – Health Policy Watch

Scientists warn of new Covid variant with high number of mutations – The Guardian

South Africa detects new COVID variant with many mutations – MedicalXpress

 

Related commentary on Twitter (thread – click for more)

 

M-A: Comparing the clinical efficacy of COVID-19 vaccines.

26 Nov, 2021 | 08:37h | UTC

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis – Scientific Reports

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.